Physician profile
Holly E Ferris
NPI 1396973905
$7,171.71
in general payments reported to CMS, 2019-2025
40 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $945 · 2023: $1,522 · 2024: $2,491 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,337.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $737.55 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $601.99 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $593.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $502.74 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $376.88 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.53 | 2022-2025 | Xifaxan, Relistor |
| Glaxosmithkline, LLC. | $310.16 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $249.57 | 2021-2025 | |
| Astellas Pharma US INC | $242.88 | 2023-2025 | Veozah |
| Amgen INC. | $152.02 | 2023-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $151.34 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $146.12 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $119.95 | 2021-2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $118.16 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $115.80 | 2025 | |
| Exact Sciences Corporation | $100.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $99.78 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $94.63 | 2024 | Voquezna |
| Corcept Therapeutics | $93.87 | 2021-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $79.28 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $57.72 | 2022-2025 | Trintellix |
| Lundbeck LLC | $57.48 | 2023-2025 | Rexulti |
| Abbott Laboratories | $56.60 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.10 | 2022-2024 | Synjardy, Tradjenta, Jardiance |
| Biohaven Pharmaceuticals, INC. | $47.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.02 | 2025 | Caplyta |
| Eisai INC. | $34.14 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.89 | 2022 | |
| Corium, LLC | $30.15 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $28.58 | 2021 | |
| Viatris Specialty LLC | $21.99 | 2025 | Yupelri |
| Inari Medical, INC. | $20.64 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ultragenyx Pharmaceutical INC. | $18.99 | 2021 | |
| Mylan Specialty L.P. | $18.40 | 2024 | Yupelri |
| Indivior INC. | $17.35 | 2025 | Sublocade |
| Amarin Pharma, INC. | $17.16 | 2021 | |
| Hologic Sales and Service, LLC | $15.85 | 2024 | Thinprep 2000 Processor, Aptima |
| Idorsia Pharmaceuticals US INC | $15.06 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Ferris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.